Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20570399 | 0.86 | MGLL (0.50) | MGLLABHD6CYP2D6PLA2G7GPR119 | |
| SCHEMBL5331677 | 0.83 | MGLL (0.68) | MGLLABHD6CYP2D6PLA2G7MAPT | |
| SCHEMBL15093970 | 0.81 | MGLL (0.74) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL30105748 | 0.81 | MGLL (0.74) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL19385731 | 0.81 | MAPT (0.54) | MGLLABHD6CYP2D6PLA2G7GPR119 | |
| SCHEMBL31142873 | 0.81 | GPR119 (0.69) | GPR119MAPTSTS | |
| SCHEMBL3922455 | 0.81 | GPR119 (0.69) | GPR119MAPTSTS | |
| SCHEMBL4511470 | 0.81 | GPR119 (0.50) | GPR119MAPT | |
| SCHEMBL28696198 | 0.81 | GPR119 (0.52) | MGLLABHD6CYP2D6PLA2G7GPR119 | |
| SCHEMBL20495447 | 0.80 | GPR119 (0.53) | MGLLABHD6CYP2D6PLA2G7GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | MGLL 986/4885ABHD6 1367/4885CYP2D6 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.